Fig. 1From: Cost-effectiveness of preemptive skin treatment to prevent skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type metastatic colorectal cancer in JapanPartitioned survival model. PFS: Progression-free survival, PPS: Post-progression survivalBack to article page